Onderzoeker
Shana Claeys
- Disciplines:Pediatrie en neonatologie, Moleculaire en celbiologie, Systeembiologie, Verpleegkunde, Genetica
Affiliaties
- Vakgroep Pediatrie en genetica (Departement)
Lid
Vanaf1 okt 2012 → 23 sep 2018
Projecten
1 - 2 of 2
- HBP1 als nieuw therapeutisch doelwit en ALK-MYCN aangedreven neuroblastoomVanaf1 okt 2016 → 30 sep 2017Financiering: VZW en equivalenten
- Functionele studie van de ALK-F1174 mutatie in neuroblastomaVanaf1 okt 2012 → 30 sep 2016Financiering: FWO mandaten, BOF - Andere acties
Publicaties
11 - 20 van 33
- Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome(2017)
Auteurs: Shana Claeys, Geertrui Denecker, Candy Kumps
Pagina's: 106820 - 106832 - The HBP1 tumour suppressor is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex(2017)
Auteurs: Shana Claeys, Geertrui Denecker, Bieke Decaesteker, Candy Kumps, Sara De Brouwer, Irina Lambertz, Annelies Fieuw, Suzanne Vanhauwaert, Kristina Althoff, Laurel Bate-Eya, et al.
Aantal pagina's: 1 - The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma(2017)
Auteurs: Irina Lambertz, Candy Kumps, Shana Claeys, Geertrui Denecker, Wouter Van Loocke, Christophe Van Neste, Jan Koster, Rogier Versteeg, Johannes Schulte
Aantal pagina's: 1 - Sensing mutant ALK: Capicua and ETV5 as executors of aberrant ALK-driven MAPK signaling(2016)
Auteurs: Irina Lambertz, Candy Kumps, Shana Claeys, Wouter Van Loocke, Christophe Van Neste, Jan Koster, Rogier Versteeg, Johannes Schulte
Aantal pagina's: 1 - Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment(2015)
Auteurs: Irina Lambertz, Candy Kumps, Shana Claeys, Sven Lindner, Anneleen Beckers, Els Janssens, Daniel R Carter, Alex Cazes, Belamy B Cheung, Marilena De Mariano, et al.
Pagina's: 3327 - 3339 - The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity
Auteurs: Shana Claeys, Candy Kumps, Irina Lambertz, Sara De Brouwer, Sven Lindner, Alan Van Goethem, Jorge Vialard, Jan Cools, Johannes Schulte
Pagina's: 114 - 115 - The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity
Auteurs: Shana Claeys, Candy Kumps, Irina Lambertz, Sara De Brouwer, Sven Lindner, Alan Van Goethem, Jorge Vialard, Jan Cools, Johannes Schulte
Pagina's: 24 - 24 - The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complexVolume: 58
Auteurs: Geertrui Denecker, Shana Claeys, Irina Lambertz, Suzanne Vanhauwaert, Bieke Decaesteker, Kristina Althoff, Johannes Schulte, Jean-Baptiste Demoulin, Stephen S Roberts, Laurel Bate-Eya, et al.
Pagina's: 1484 - 1484 - Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment
Auteurs: Irina Lambertz, Candy Kumps, Shana Claeys, Sven Lindner, Anneleen Beckers, Daniel Carter, Alex Cazes, Belamy Cheung, Marilena De Mariano, David Camacho-Trujillo, et al.
Aantal pagina's: 1 - The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex
Auteurs: Shana Claeys, Irina Lambertz, Suzanne Vanhauwaert, Bieke Decaesteker, Candy Kumps, Sara De Brouwer, Annelies Fieuw, Kristina Althoff, Johannes Schulte, Laurel Bate-eya, et al.
Aantal pagina's: 1